ABVX

73.2009.24%
SL

Sylvie L. Gregoire

Co-Founder & Director

Dr. Sylvie L. Gregoire, Pharm.D. is Non-Executive Director of F2G Ltd. Dr. Gregoire is Independent Chair of the Board of ABIVAX Société Anonyme from July 11, 2024. Dr. Gregoire had been an Independent Director of Revvity, Inc. (formerly known as PerkinElmer, Inc.) since February 6, 2015 until April 2024. Dr. Gregoire is the Co-Founder of CervoMed Inc. (Formerly, EIP Pharma, Inc.) since August 2023 and was Executive Chair of CervoMed Inc. (Formerly, EIP Pharma, Inc.) since August 2023 until February 2024 and also serves as its Director since 2023. Dr. Gregoire serves as Advisor to venture capital and biotech companies. She had been Executive Chairman of Board at MetrioPharm AG since June 24, 2016. Dr. Gregoire served as the President of Human Genetic Therapies, Inc. at Shire plc from September 24, 2007 to March 31, 2013. She served as the President and Chief Executive Officer of GlycoFi, Inc. from 2004 to 2005. She served as a Consultant to the biopharmaceutical industry from December 2003 to September 2004. She served as an Executive Vice President of Technical Operations at Biogen MA Inc. from August 2001 to December 2003 and its Vice President of Manufacturing from October 2000 to August 2001, Vice President of Regulatory Affairs from January 1999 to October 2000, Program Executive for Biogen’s LT-Beta Receptor program from July 1998 to January 1999 and Director of European Regulatory Affairs from 1995 to July 1998. Dr. Grégoire served as a Member of the Management Team of Biogen Inc. from 1995 to 2003. She served as President of Worldwide Regulatory Affairs and Executive Vice President of Technical Operations at Biogen Inc. She served as an Associate Director of European Regulatory Affairs at Merck Sharp and Dohme (Europe) Inc. from 1991 to 1994 and also served various positions at Merck & Company from 1987 to 1995. She had been the Chair of Corvidia Therapeutics, Inc. since June 14, 2016 until 2020. She served as an Executive Chairman of IDM Pharma, Inc. from August 2006 to October 2007. She served as the Chairman of the Board of Supervisors at Shire Orphan Therapies GmbH since September 2008. She was Director of Novo Nordisk A/S since March 19, 2015 until November 15, 2025. She serves as Director at PerkinElmer LAS (Germany) GmbH. She had been a Director of Vifor Pharma AG since 2013 until May 8, 2019. She serves as a Director of the Greater Boston Food Bank. She serves on the Board of Trustees at the International School of Boston. She served as a Member of Board of Supervisors at Shire Orphan Therapies GmbH since September 2008. She served as a Director of Cubist Pharmaceuticals LLC from June 12, 2006 to May 19, 2011. She served as a Director of IDM Pharma, Inc. from August 2005 to April 30, 2008, GlycoFi Inc. from October 2004 to August 2005 and Thallion Pharmaceuticals, Inc. until December 10, 2007. She served as a Director of Caprion Pharmaceuticals, Inc. She served as a Director of Epimmune Inc. since August 2005. She served as a Member of the Boards of Directors of various companies in the USA and Canada and the boards of various charitable organisations. She published papers and presented abstracts in the United States and Canada on pharmacokinetics of pharmaceutical drugs including antibacterials. Dr. Grégoire has a Pharmacy Doctorate degree from the State University of NY at Buffalo, US, BA in Pharmacy from Laval University, Canada and College degree in Science in 1980 from Séminaire de Sherbrooke, Canada.

Positions